Pages that link to "Q38289096"
Jump to navigation
Jump to search
The following pages link to A-to-I RNA Editing Up-regulates Human Dihydrofolate Reductase in Breast Cancer (Q38289096):
Displaying 19 items.
- RNA editing of SLC22A3 drives early tumor invasion and metastasis in familial esophageal cancer. (Q45346268) (← links)
- When MicroRNAs Meet RNA Editing in Cancer: A Nucleotide Change Can Make a Difference (Q47252687) (← links)
- RNA-editing enzymes ADAR1 and ADAR2 coordinately regulate the editing and expression of Ctn RNA. (Q47917018) (← links)
- The role of A-to-I RNA editing in cancer development (Q50060481) (← links)
- The Role of RNA Editing in Cancer Development and Metabolic Disorders (Q60949658) (← links)
- ADAR1 Editing and its Role in Cancer (Q61813334) (← links)
- Tumor-associated intronic editing of HNRPLL generates a novel splicing variant linked to cell proliferation (Q88698322) (← links)
- Identification of Adenosine-to-Inosine RNA Editing with Acrylonitrile Reagents (Q90085868) (← links)
- Dysregulations of Functional RNA Modifications in Cancer, Cancer Stemness and Cancer Therapeutics (Q90481772) (← links)
- Transcriptome-wide identification of A-to-I RNA editing sites using ICE-seq (Q90714721) (← links)
- Clinical Theragnostic Relationship between Drug-Resistance Specific miRNA Expressions, Chemotherapeutic Resistance, and Sensitivity in Breast Cancer: A Systematic Review and Meta-Analysis (Q90724866) (← links)
- Regulation of microRNA function in animals (Q90947514) (← links)
- Novel insight into the regulatory roles of diverse RNA modifications: Re-defining the bridge between transcription and translation (Q92022443) (← links)
- Current trends in drug metabolism and pharmacokinetics (Q92190037) (← links)
- Knockdown of long noncoding RNA TP73-AS1 suppresses the malignant progression of breast cancer cells in vitro through targeting miRNA-125a-3p/metadherin axis (Q92412493) (← links)
- ADAR, the carcinogenesis mechanisms of ADAR and related clinical applications (Q92593887) (← links)
- LncRNA MEG3 acts a biomarker and regulates cell functions by targeting ADAR1 in colorectal cancer (Q92626031) (← links)
- Epitranscriptomics and epiproteomics in cancer drug resistance: therapeutic implications (Q99233801) (← links)
- Evaluating the therapeutic potential of ADAR1 inhibition for triple-negative breast cancer (Q101038961) (← links)